Business
Representatives of Fulgent Genetics to Participate in Upcoming Virtual Conferences
TEMPLE CITY, Calif.--(BUSINESS WIRE)-- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology-based genetic testing
About this update from Fulgent Genetics, Inc.
[{"type":"text","content":" TEMPLE CITY, Calif.--(BUSINESS WIRE)--\nFulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that members of its management team are scheduled to virtually participate in the following investor conferences:\n\nCredit Suisse 30th Annual Healthcare Conference\nWednesday, November 10, 2021\nLive presentation at 4:20 p.m. Eastern Time (1:20 p.m. Pacific Time)\n\nPiper Jaffray 33rd Annual Healthcare Conference\nWednesday, December 1, 2021\n\nWebcasts of the presentations will be available on the Investor Relations section of the Fulgent Genetics website at ir.fulgentgenetics.com.\n\nAbout Fulgent Genetics\n\nFulgent Genetics is a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health. Fulgent’s proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy, and competitive turnaround times. Combining next generation sequencing (“NGS”) with its technology platform, the Company performs full-gene sequencing with deletion/duplication analysis in an array of panels that can be tailored to meet specific customer needs. A cornerstone of the Company’s business is its ability to provide expansive options and flexibility for all clients’ unique testing needs through a comprehensive technology offering including cloud computing, pipeline services, record management, web portal services, clinical workflow, sequencing as a service and automated lab services.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20211109005721/en/\n\nInvestor Relations Contacts:\nThe Blueshirt Group\nNicole Borsje, 415-217-2633, [email protected]\n\nSource: Fulgent Genetics, Inc.","length":3452,"tagName":"div"}]